ASCO Annual Meeting 2018
Meet with Q2 Solutions at ASCO’s Annual Meeting 2018 and learn how our industry leading central lab capabilities can enhance and accelerate your oncology research
About This EventFrom biomarkers, companion diagnostics, esoteric testing, bioinformatics and analytics, to robust logistics and sample management, Q2 Solutions is committed to help power your oncology study every step of the way.
Through our Oncology Center of Excellence, our experts in biomarker discovery can provide you with a better understanding of therapeutic targets, molecular signaling, drug biology and patient response. We can help you develop dramatically more efficient means of enrolling rare, biomarker-defined patients by leveraging next-generation sequencing and our established site relationships.
Through carefully orchestrated analyses, we work with you to choose platforms and assays that will distinctly fit your oncology needs, and then use them to deliver quality informative data. Leveraging our breakthrough genomic know-how®, Q2 Solutions is your best partner in optimizing oncology treatment decisions and ensuring that the right drug is used to treat the right patient at the right time.
Schedule a meeting with our team at ASCO 2018 to learn how our deep scientific expertise and industry-leading technology, can help you harness the latest wave of progress against cancer.
We look forward to meeting you in Chicago.
Scientific Advisor, Flow Cytometry
Mark Edinger is the scientific advisor for Flow Cytometry at Q2 Solutions. As the scientific advisor, Mark is responsible for flow cytometry assay design and implementation. He works with both the Translational Biomarkers Laboratory to develop assays and the Global Cytometry Group to produce assays, and is the architect of the systems and workflows used in Q2 Solutions’ flow cytometry assay development and production laboratories.
Mark began his career at the Cleveland Clinic Foundation, a preeminent medical institution, where he pioneered flow cytometry in the late 1970s, building both clinical and research core flow cytometry laboratories. During his 21 years at the Cleveland Clinic, Mark developed many of the techniques and assays employed today for clinical practice and academic research. During this time, Mark also was a consultant for Becton Dickinson (BD) Immunocytometry Systems and participated in clinical trials of new BD products. In 1998, Mark formally joined BD where he founded the Technical Applications Group, and later the R&D Systems Validation Laboratory. While at BD, Mark, working with scientists at Amgen, developed the whole blood phosphoprotein lysing buffer that is now used daily in laboratories throughout the world. Mark joined Quintiles in 2012 and has been part of a collaboration which introduced the quantitative standardization of flow cytometers, along with other state of the art practices, making Quintiles flow laboratories the first to offer this level of instrument standardization anywhere in the world. Mark became part of the Q2 Solutions team when the company was officially launched in June 2015 as a result of a Quintiles and Quest Diagnostics joint venture.
Mark graduated from Case Western Reserve University with a Bachelor of Science degree in Biology.